JP2010534469A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010534469A5 JP2010534469A5 JP2010517493A JP2010517493A JP2010534469A5 JP 2010534469 A5 JP2010534469 A5 JP 2010534469A5 JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010517493 A JP2010517493 A JP 2010517493A JP 2010534469 A5 JP2010534469 A5 JP 2010534469A5
- Authority
- JP
- Japan
- Prior art keywords
- monoclonal antibody
- human
- kdr
- monoclonal
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 102100040681 Platelet-derived growth factor C Human genes 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 210000002889 endothelial cell Anatomy 0.000 claims 2
- 102000058223 human VEGFA Human genes 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 238000000034 method Methods 0.000 claims 2
- 230000001613 neoplastic effect Effects 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 230000026731 phosphorylation Effects 0.000 claims 2
- 238000006366 phosphorylation reaction Methods 0.000 claims 2
- 108010017992 platelet-derived growth factor C Proteins 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- 210000003606 umbilical vein Anatomy 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 238000002965 ELISA Methods 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 238000003556 assay Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 238000006471 dimerization reaction Methods 0.000 claims 1
- 208000030533 eye disease Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 210000004408 hybridoma Anatomy 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 239000006228 supernatant Substances 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US95180507P | 2007-07-25 | 2007-07-25 | |
| PCT/GB2008/050615 WO2009013543A2 (en) | 2007-07-25 | 2008-07-23 | Targeted binging agents directed to kdr and uses thereof - 035 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010534469A JP2010534469A (ja) | 2010-11-11 |
| JP2010534469A5 true JP2010534469A5 (enExample) | 2011-09-08 |
Family
ID=40281893
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010517493A Pending JP2010534469A (ja) | 2007-07-25 | 2008-07-23 | Ｋｄｒ指向性標的化結合物質およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US8119130B2 (enExample) |
| EP (1) | EP2183028A2 (enExample) |
| JP (1) | JP2010534469A (enExample) |
| AU (1) | AU2008278803A1 (enExample) |
| CA (1) | CA2694396A1 (enExample) |
| WO (1) | WO2009013543A2 (enExample) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010534469A (ja) | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | Ｋｄｒ指向性標的化結合物質およびその使用 |
| JO3375B1 (ar) * | 2010-11-08 | 2019-03-13 | Regeneron Pharma | أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a) |
| LT3075745T (lt) | 2011-02-10 | 2018-11-26 | Roche Glycart Ag | Mutavę interleukino-2 polipeptidai |
| EA201892619A1 (ru) | 2011-04-29 | 2019-04-30 | Роше Гликарт Аг | Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2 |
| BR112014010774A2 (pt) | 2011-11-02 | 2017-06-13 | Apexigen Inc | anticorpos anti-kdr e métodos de uso |
| CN104650229A (zh) * | 2011-11-02 | 2015-05-27 | 埃派斯进有限公司 | 抗-kdr抗体和使用方法 |
| US20140044675A1 (en) | 2012-08-10 | 2014-02-13 | Roche Glycart Ag | Interleukin-2 fusion proteins and uses thereof |
| JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
| PL3489261T3 (pl) | 2012-08-24 | 2021-08-16 | The Regents Of The University Of California | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu |
| KR102117969B1 (ko) * | 2012-09-12 | 2020-06-04 | 뉴리뮨 홀딩 아게 | 인간 섬 아밀로이드 폴리펩티드(hiapp) 특이적 항체 및 이들의 용도 |
| PE20161324A1 (es) | 2014-02-06 | 2016-11-25 | Hoffmann La Roche | Proteinas de fusion de interleucina-2 y usos de las mismas |
| WO2017004254A1 (en) * | 2015-06-30 | 2017-01-05 | Wei-Dong Jiang | Anti-vascular endothelial growth factor receptor 2 (vegfr2) antibodies |
| CA3029003A1 (en) | 2016-06-27 | 2018-01-04 | The Regents Of The University Of California | Cancer treatment combinations |
| CN110944651A (zh) | 2017-02-08 | 2020-03-31 | 蜻蜓疗法股份有限公司 | 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途 |
| US20200095327A1 (en) * | 2017-02-08 | 2020-03-26 | Dragonfly Therapeutics, Inc. | Antibody heavy chain variable domains targeting the nkg2d receptor |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| SG11201907848YA (en) | 2017-03-14 | 2019-09-27 | Five Prime Therapeutics Inc | Antibodies binding to vista at acidic ph |
| CN111601616A (zh) | 2017-10-24 | 2020-08-28 | 美真达治疗公司 | 用于耗尽cd117+细胞的组合物和方法 |
| JP7280254B2 (ja) | 2017-10-24 | 2023-05-23 | マジェンタ セラピューティクス インコーポレイテッド | Ｃｄ１１７＋細胞を減少させるための組成物及び方法 |
| WO2019084053A1 (en) * | 2017-10-24 | 2019-05-02 | Magenta Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR DEPLOYING CD117 + CELLS |
| CA3090236A1 (en) | 2018-02-08 | 2019-08-15 | Dragonfly Therapeutics, Inc. | Combination therapy of cancer involving multi-specific binding proteins that activate natural killer cells |
| SG11202007482WA (en) | 2018-02-08 | 2020-09-29 | Dragonfly Therapeutics Inc | Antibody variable domains targeting the nkg2d receptor |
| KR102832460B1 (ko) | 2018-02-20 | 2025-07-11 | 드래곤플라이 쎄라퓨틱스, 인크. | Cd33, nkg2d, 및 cd16에 결합하는 다중-특이적 결합 단백질, 및 이의 사용 방법 |
| MX2020009786A (es) | 2018-03-21 | 2020-10-12 | Five Prime Therapeutics Inc | Anticuerpos de union a supresor de la activacion de celulas t que contiene el dominio variable de inmunoglobulina (vista) a ph acido. |
| US12091462B2 (en) | 2018-07-11 | 2024-09-17 | Five Prime Therapeutics, Inc. | Antibodies binding to vista at acidic pH |
| MA53293A (fr) | 2018-08-08 | 2021-11-17 | Dragonfly Therapeutics Inc | Protéines de liaison multi-spécifiques se liant à bcma, nkg2d et cd16, et méthodes d'utilisation |
| MX2021001527A (es) | 2018-08-08 | 2021-06-15 | Dragonfly Therapeutics Inc | Proteínas de unión a nkg2d, cd16 y a un antígeno asociado a tumor. |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| MX2022013944A (es) | 2020-05-06 | 2022-11-30 | Dragonfly Therapeutics Inc | Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a). |
| WO2022187539A1 (en) | 2021-03-03 | 2022-09-09 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16 and a tumor-associated antigen |
| KR20240040783A (ko) * | 2021-07-29 | 2024-03-28 | 소노마 바이오테라퓨틱스, 인크. | 자가면역 질환을 치료하기 위한 조절 t 세포를 표적화하는 윤활 세포외 기질-특이적 키메라 항원 수용체 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL159177A0 (en) * | 2001-06-20 | 2004-06-01 | Prochon Biotech Ltd | Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| EP1411983A4 (en) * | 2001-06-26 | 2006-06-21 | Imclone Systems Inc | BISPECIFIC ANTIBODIES BINDING TO VEGF RECEPTORS |
| CA2478169C (en) * | 2002-03-04 | 2013-04-16 | Imclone Systems Incorporated | Human antibodies specific to kdr and uses thereof |
| JP2010534469A (ja) | 2007-07-25 | 2010-11-11 | アストラゼネカ アクチボラグ | Ｋｄｒ指向性標的化結合物質およびその使用 |
-
2008
- 2008-07-23 JP JP2010517493A patent/JP2010534469A/ja active Pending
- 2008-07-23 WO PCT/GB2008/050615 patent/WO2009013543A2/en not_active Ceased
- 2008-07-23 US US12/669,724 patent/US8119130B2/en not_active Expired - Fee Related
- 2008-07-23 AU AU2008278803A patent/AU2008278803A1/en not_active Abandoned
- 2008-07-23 EP EP08788590A patent/EP2183028A2/en not_active Withdrawn
- 2008-07-23 CA CA2694396A patent/CA2694396A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010534469A5 (enExample) | ||
| JP2014503189A5 (enExample) | ||
| Liang et al. | Cationic nanoparticle as an inhibitor of cell-free DNA-induced inflammation | |
| JP2014530215A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2019519199A5 (enExample) | ||
| JP2015227342A5 (enExample) | ||
| JP2018108081A5 (enExample) | ||
| JP2013529183A5 (enExample) | ||
| JP2012012402A5 (enExample) | ||
| JP2017523786A5 (enExample) | ||
| HRP20161069T1 (hr) | Molekule antitijela koje vezuju il-17a i il-17f | |
| JP2015517300A5 (enExample) | ||
| JP2010506596A5 (enExample) | ||
| JP2010507594A5 (enExample) | ||
| JP2011515073A5 (enExample) | ||
| JP2020504076A5 (enExample) | ||
| JP2017504577A5 (enExample) | ||
| CA2798390A1 (en) | Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (lrp6) multivalent antibodies | |
| JP2010535032A5 (enExample) | ||
| JP2015212281A5 (enExample) | ||
| JP2019506842A5 (enExample) | ||
| CL2010001544A1 (es) | Anticuerpo monoclonal humanizado o fragmento de union al mismo que se une y neutraliza al factor de crecimiento endotelial vascular humano (hvegf); composicion que lo comprende; acido nucleico codificante; vector; celula huesped; su uso para tratar o prevenir una enfermedad mediada por vegf; e hibridoma. | |
| FI3736291T3 (fi) | Anti-fcrh5-vasta-aineita | |
| JP2010538608A5 (enExample) |